Debt-to-equity of Benitec Biopharma Inc. from 31 Mar 2021 to 31 Dec 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Benitec Biopharma Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2021 to 31 Dec 2025.
  • Benitec Biopharma Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was 3.3%, a 59% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Benitec Biopharma Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q4 2025 3.3% -4.8% -59% 31 Dec 2025
Q3 2025 4.2% -9.4% -69% 30 Sep 2025
Q2 2025 5.3% -15% -73% 30 Jun 2025
Q1 2025 7.1% -30% -81% 31 Mar 2025
Q4 2024 8.1% -35% -81% 31 Dec 2024
Q3 2024 14% -29% -68% 30 Sep 2024
Q2 2024 20% -30% -60% 30 Jun 2024
Q1 2024 37% -4.5% -11% 31 Mar 2024
Q4 2023 43% +7.7% +22% 31 Dec 2023
Q3 2023 43% +8.2% +24% 30 Sep 2023
Q2 2023 50% +19% +63% 30 Jun 2023
Q1 2023 42% +24% +138% 31 Mar 2023
Q4 2022 35% +19% +116% 31 Dec 2022
Q3 2022 34% +23% +195% 30 Sep 2022
Q2 2022 30% +19% +173% 30 Jun 2022
Q1 2022 18% +4% +29% 31 Mar 2022
Q4 2021 16% 31 Dec 2021
Q3 2021 12% 30 Sep 2021
Q2 2021 11% 30 Jun 2021
Q1 2021 14% 31 Mar 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.